Literature DB >> 17397679

Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits.

Kumiko Arishiro1, Masaaki Hoshiga, Nobuyuki Negoro, Denan Jin, Shinji Takai, Mizuo Miyazaki, Tadashi Ishihara, Toshiaki Hanafusa.   

Abstract

OBJECTIVES: We sought to examine the effect of angiotensin receptor blocker (ARB) on the formation of lesions in the aortic valves of hypercholesterolemic rabbits.
BACKGROUND: Recently, atherosclerosis has been recognized as a mechanism that is responsible for calcific aortic stenosis. The effect of ARBs might help to prevent aortic stenosis because they have multiple antiatherosclerotic effects.
METHODS: Male Japanese white rabbits (n = 36) were separated as follows: control with chow diet (C) and vehicle (V) groups, both of which were fed a 1% cholesterol diet for 8 weeks, and an ARB group (A), which was fed a 1% cholesterol diet for 8 weeks with ARB (olmesartan, 1 mg/kg/day) for the last 4 weeks.
RESULTS: This dose of olmesartan did not affect either blood pressure or cholesterol levels. Dietary cholesterol induced fatty deposition with macrophage accumulation and osteopontin coexpression in valve leaflets, whereas ARB decreased macrophage accumulation (% area: V, 9.3 +/- 0.34; A, 1.4 +/- 0.30; p = 0.003) and osteopontin expression (p = 0.017). Angiotensin-converting enzyme was also up-regulated in V and decreased by olmesartan (p = 0.015). Immunohistochemistry with anti-CD31 antibody revealed that dietary cholesterol disrupted and olmesartan preserved endothelial integrity on the lesion-prone aortic side of the valve (% CD31-positive circumference: V, 30 +/- 3.7; A, 62 +/- 4.8; p = 0.003). Numbers of alpha-smooth muscle actin-positive myofibroblasts were increased in V and decreased by olmesartan (p = 0.003). Real-time polymerase chain reaction revealed that increased amounts of messenger ribonucleic acid for osteoblast-specific transcription factor core binding factor alpha-1 in V were diminished by olmesartan.
CONCLUSIONS: Atherosclerotic changes in the aortic valves of rabbits fed with cholesterol were inhibited by ARB, whereas endo-thelial integrity was preserved and transdifferentiation into myofibroblasts and/or osteoblasts in valve leaflets was inhibited.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17397679     DOI: 10.1016/j.jacc.2006.11.043

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  37 in total

1.  Risk factors for progression of calcific aortic stenosis and potential therapeutic targets.

Authors:  Ashvin R Kamath; Ramdas G Pai
Journal:  Int J Angiol       Date:  2008

2.  Changes in blood pressure during induction of anesthesia and oral and maxillofacial surgery by type and timing of discontinuation of antihypertensive drugs.

Authors:  Yoshihiro Momota; Kazuhiro Kaneda; Kumiko Arishiro; Naotaka Kishimoto; Seiji Kanou; Junichiro Kotani
Journal:  Anesth Prog       Date:  2010

3.  Effect of hydroxymethylglutaryl coenzyme-a reductase inhibitors on the long-term progression of rheumatic mitral valve disease.

Authors:  Francesco Antonini-Canterin; Luis M Moura; Roxana Enache; Elisa Leiballi; Daniela Pavan; Rita Piazza; Bogdan A Popescu; Carmen Ginghina; Gian Luigi Nicolosi; Nalini M Rajamannan
Journal:  Circulation       Date:  2010-05-03       Impact factor: 29.690

Review 4.  Calcific aortic valve stenosis: methods, models, and mechanisms.

Authors:  Jordan D Miller; Robert M Weiss; Donald D Heistad
Journal:  Circ Res       Date:  2011-05-27       Impact factor: 17.367

Review 5.  Potential drug targets for calcific aortic valve disease.

Authors:  Joshua D Hutcheson; Elena Aikawa; W David Merryman
Journal:  Nat Rev Cardiol       Date:  2014-01-21       Impact factor: 32.419

6.  Valsartan Attenuates Atherosclerosis via Upregulating the Th2 Immune Response in Prolonged Angiotensin II-Treated ApoE(-/-) Mice.

Authors:  Kai Meng; Qiutang Zeng; Qinghua Lu; Yingzhong Lin; Bangwei Wu; Kunwu Yu; Zhaoqiang Dong; Jianwei Zhang; Meng Chai; Yuyang Liu; Qingwei Ji; Yujie Zhou
Journal:  Mol Med       Date:  2015-02-09       Impact factor: 6.354

Review 7.  Calcific aortic valve disease: is it another face of atherosclerosis?

Authors:  I Sathyamurthy; Shaji Alex
Journal:  Indian Heart J       Date:  2015-08-21

8.  Reduction of Cardiovascular Risk through Angiotensin II Type 1 Receptor Antagonism : Focus on Olmesartan Medoxomil.

Authors:  Enrico Agabiti Rosei
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-22

Review 9.  Calcific aortic stenosis.

Authors:  Brian R Lindman; Marie-Annick Clavel; Patrick Mathieu; Bernard Iung; Patrizio Lancellotti; Catherine M Otto; Philippe Pibarot
Journal:  Nat Rev Dis Primers       Date:  2016-03-03       Impact factor: 52.329

10.  ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model.

Authors:  Mikko A Simolin; Tanja X Pedersen; Susanne Bro; Mikko I Mäyränpää; Satu Helske; Lars B Nielsen; Petri T Kovanen
Journal:  BMC Cardiovasc Disord       Date:  2009-03-03       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.